NORD Slams Orphan Indication Discussion At Biosimilar Advisory Committee

For one rare disease advocate, simply soliciting advisory committee comments on extrapolating Remicade's orphan indication before its exclusivity expires could weaken rare disease drug development.

The National Organization for Rare Disorders gave a scathing critique of FDA's decision to place the pediatric ulcerative colitis indication for Janssen Biotech Inc